Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Justin Franklin Gainor, M.D.

Co-Author

This page shows the publications co-authored by Justin Gainor and Biagio Ricciuti.
Connection Strength

0.788
  1. Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status. J Thorac Oncol. 2022 Mar; 17(3):399-410.
    View in: PubMed
    Score: 0.242
  2. Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC. JTO Clin Res Rep. 2020 Nov; 1(4):100074.
    View in: PubMed
    Score: 0.221
  3. Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression =50. Ann Oncol. 2020 03; 31(3):404-411.
    View in: PubMed
    Score: 0.212
  4. Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancer. J Immunother Cancer. 2021 11; 9(11).
    View in: PubMed
    Score: 0.060
  5. Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression. Ann Oncol. 2019 10 01; 30(10):1653-1659.
    View in: PubMed
    Score: 0.052
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.